Compare MGF & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGF | MAIA |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.9M | 79.0M |
| IPO Year | N/A | 2022 |
| Metric | MGF | MAIA |
|---|---|---|
| Price | $2.85 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 134.3K | ★ 989.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 7.64% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $0.87 |
| 52 Week High | $3.14 | $3.19 |
| Indicator | MGF | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 55.75 |
| Support Level | N/A | $1.22 |
| Resistance Level | $2.94 | $1.50 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 41.67 | 48.39 |
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.